Source: International Congress 2016 – Clinic of pulmonary hypertension
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Anne Roche (Paris, France), Anne Roche, Marie Camille Chaumais, Swanny Perrin, Xavier Jaïs, Laurent Savale, Philippe Camus, Nicolas Favrolt, Julie Traclet, Vincent Cottin, Olivier Sitbon, Gerald Simmoneau, Marc Humbert, Philippe Bonniaud, David Montani. Illicit drug use and pulmonary arterial hypertension: Not so frequent. Eur Respir J 2016; 48: Suppl. 60, 259

Member's Comments

No comment yet.

Related content which might interest you: Pregnancy and pulmonary hypertension: Experience of a reference center in Brazil Source: Annual Congress 2013 –Pulmonary circulation: clinical pulmonary hypertension II Year: 2013 Macitentan for pulmonary arterial hypertension (PAH): Early clinical experience of 94 patients Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Riociguat for the treatment of pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension: Real-life data from the EXPERT registry Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Female pulmonary arterial hypertension is associated with decreased microRNA96 expression Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Global fibrinolytic profile in patients with chronic thromboembolic pulmonary hypertension Source: International Congress 2015 – Pulmonary circulation: pulmonary embolism and chronic thromboembolic pulmonary hypertension Year: 2015 Global burden of chronic thromboembolic pulmonary hypertension (CTEPH): An epidemiological analysis Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Cardiopulmonary comorbidities are associated with hemodynamics in pulmonary arterial hypertension Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Smad1 deficiency and female gender contribute to the development of pulmonary hypertension Source: International Congress 2014 – Pathobiology of pulmonary hypertension Year: 2014 Pulmonary arterial hypertension associated to HIV. Our experience Source: International Congress 2015 – Pulmonary hypertension: rare and hereditary causes of PAH Year: 2015 Specific pulmonary arterial hypertension therapy in COPD patients with severe pulmonary hypertension Source: International Congress 2014 – Pulmonary hypertension in lung disease Year: 2014 Adherence to pulmonary arterial hypertension targeted therapies Source: International Congress 2015 – Pulmonary hypertension: management Year: 2015 Long-term data from the Swiss pulmonary hypertension registry Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 PAH-specific therapies improve survival in patients with pulmonary arterial hypertension associated with connective tissue diseases: A Russian single centre experience Source: International Congress 2014 – Pulmonary hypertension: novel targets and drugs Year: 2014 Epoprostenol dosing by concomitant therapies in the PROSPECT registry Source: International Congress 2014 – Pulmonary hypertension: clinical management Year: 2014 Unique characteristics of patients with pulmonary arterial hypertension associated with congenital heart disease compared to the rest of pulmonary arterial hypertension subgroups Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Safety and long-term efficacy of transition from sildenafil to tadalafil due to side effects in patients with pulmonary arterial hypertension Source: International Congress 2014 – Modern approach and old dilemmas in lung diseases Year: 2014 The incidence of chronic thromboembolic pulmonary hypertension secondary to acute pulmonary thromboembolism Source: International Congress 2014 – Chronic thromboembolic pulmonary hypertension Year: 2014 Sildenafil improves heart rate variability, pulmonary hemodynamics and functional status in pulmonary arterial hypertension Source: International Congress 2014 – Pulmonary hypertension: right ventricle and basic physiology Year: 2014 Limited and heterogeneous arterial narrowing in idiopathic pulmonary hypertension: Rethinking resistance Source: International Congress 2015 – Pulmonary hypertension: the right ventricle and its load Year: 2015 LATE-BREAKING ABSTRACT: Riociguat for the treatment of pulmonary arterial hypertension (PAH): 2-year results from the PATENT-2 long-term extension Source: International Congress 2014 – New technologies and biomarkers in lung disease Year: 2014